Literature DB >> 17942467

Balanced two-stage designs for phase II clinical trials.

Fei Ye1, Yu Shyr.   

Abstract

BACKGROUND: Oncology phase II clinical trials are often designed using Simon's two-stage designs (optimal and 'minimax') for independent observations. Simon's designs do not include the use of correlated observations, and do not balance the sample sizes of the two stages. In these designs, the sample sizes of the two stages can be highly unequal. In certain circumstances, an alternative design option that balances the sample sizes is desirable.
PURPOSE: To develop a two-stage phase II design that balances the sample sizes of the first and the second stages, while controlling for type I and type II error rates.
METHODS: We simulated designs based on response rates under various null and alternative hypotheses, type I and type II error constraints, and the degree of correlation in the case of correlated data. For correlated data, Sargent's method is adopted to account for the loss of information due to intra-person correlation.
RESULTS: Design characteristics for different parameter settings were generated using balanced design method, separately for independent and correlated data. Results were evaluated and compared to the optimal and minimax design. LIMITATIONS: For correlated data, designs were produced only for trials with half of the participants having one observation and the other half having two. Also, the degree of intra-person correlation was fixed at three levels.
CONCLUSION: The balanced design provides an additional choice for two-stage phase II trials when the investigators would like to monitor the trial near a study's halfway point. Meanwhile, its total sample sizes are comparable with Simon's designs.

Entities:  

Mesh:

Year:  2007        PMID: 17942467     DOI: 10.1177/1740774507084102

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  7 in total

1.  Suspension of accrual in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2015-01-07       Impact factor: 2.486

2.  VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

Authors:  Julie E Chang; Christopher Peterson; Sangbum Choi; Jens C Eickhoff; KyungMann Kim; David T Yang; Leslie A Gilbert; Eric S Rogers; Jae E Werndli; Michael S Huie; Thomas A McFarland; Michael Volk; Jules Blank; Natalie S Callander; Walter L Longo; Brad S Kahl
Journal:  Br J Haematol       Date:  2011-08-16       Impact factor: 6.998

3.  A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2012-04-20       Impact factor: 2.486

4.  Stopping for efficacy in single-arm phase II clinical trials.

Authors:  Rezoanoor Rahman; M Iftakhar Alam
Journal:  J Appl Stat       Date:  2021-03-21       Impact factor: 1.416

5.  Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.

Authors:  Guan-Zhong Zhang; Shun-Chang Jiao; Zhao-Ting Meng
Journal:  J Exp Clin Cancer Res       Date:  2010-04-27

6.  A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.

Authors:  Michelle DeVeaux; Michael Kane; Wei Wei; Daniel Zelterman
Journal:  Pharm Stat       Date:  2019-09-10       Impact factor: 1.894

7.  Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.

Authors:  A P Mander; S G Thompson
Journal:  Contemp Clin Trials       Date:  2010-08-01       Impact factor: 2.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.